Trial Profile
Neoadjuvant S-1 therapy for resectable pancreatic cancer patients; A phase 2 study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2019
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 18 Mar 2019 Status changed from active, no longer recruiting to completed.
- 16 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2014 New trial record